Table 1 Survival outcomes of standard dose or high dose in esophageal cancer dCRT from selected trails
Study (Reference) | Country (Year*) | Pathology | Radiation dose | Radiation technique | Systemic therapies | No. of Patients | 2y OS | 3y OS | 5y OS |
|---|---|---|---|---|---|---|---|---|---|
RTOG 85–01 [5] | USA (1986–1990) | AC/SCC | 50 Gy | 2D | DDP + 5-Fu | 61 | 36% | 30% | 25% |
50 Gy | DDP + 5-Fu | 69 | 36% | 30% | 25% | ||||
64 Gy | – | 62 | 10% | 0% | 0% | ||||
RTOG 94–05/INT 0123 [6] | USA (1995–1999) | AC/SCC | 50.4 Gy | 2D | DDP + 5-Fu | 109 | 40% | 33% | – |
64.8 Gy | DDP + 5-Fu | 109 | 31% | 25% | – | ||||
PRODIGE5/ACCORD17 [7] | France (2004–2011) | AC/SCC | 50 Gy | 3DCRT | FOLFOX | 134 | – | 19.9% | – |
DDP + 5-Fu | 133 | – | 26.9% | – | |||||
SCOPE1 [8] | UK (2008–2012) | AC/SCC | 50 Gy | 3DCRT | CAP + DDP + Cetuximab | 129 | 41.3% | – | – |
CAP + DDP | 129 | 56% | – | – | |||||
RTOG 0436 [9] | USA (2008–2013) | AC/SCC | 50.4 Gy | 3DCRT | PTX + DDP + Cetuximab | 159 | 45% | 34% | – |
PTX + DDP | 169 | 44% | 28% | – | |||||
CONCORDE/PRODIGE26 [10] | France (2011–2019) | AC/SCC | 50 Gy | 3DCRT/IMRT/VMAT | FOLFOX | 109 | Median 25.2 m | ||
66Â Gy | 108 | Median 23.5Â m | |||||||
ESO-Shanghai 1 [17] | China (2012–2015) | SCC | 61.2 Gy | IMRT | PTX + 5-Fu | 217 | 60.6 | 55.4% | 44.3% |
DDP + 5-Fu | 219 | 61.5% | 51.8% | 40.8% | |||||
ARTDECO [11] | Netherlands (2012–2018) | AC/SCC | 50.4 Gy | 3DCRT/IMRT | PTX + CBP | 130 | – | 42% | – |
61.6 Gy | 130 | – | 39% | – | |||||
Xu et al. [12] | China (2013–2017) | SCC | 50 Gy | IMRT | DDP + DTX | 153 | 62.9% | 54.0% | – |
60 Gy | 152 | 64.8% | 54.1% | – | |||||